

### **Abstract**

This invention provides a method of therapeutical conversion from a long-acting release (LAR) formulation of octreotide, e.g. Sandostatin® LAR®, to pegvisomant (Somavert®) for the acromegalic patients through a therapeutically overlapping transition period to a final dose range of pegvisomant established.